Results 81 to 90 of about 8,561 (174)

Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort

Epilepsia Open, Volume 11, Issue 4, Page 1255-1262, August 2026.
Abstract Objective To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation. Methods We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective ...
Marina Feldman, Andreas Alexopoulos, Juan Bulacio, Dileep Nair, Vineet Punia   +4 more
wiley   +1 more source

A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy

Pediatric Health, Medicine and Therapeutics, 2014
Maria Stella Vari, Pasquale Striano Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, "G Gaslini" Institute, Genova, Italy ...
Vari MS, Striano P
doaj  

Targeting Oxidative Stress and Neuro-Inflammation by Gastrodia elata Improves Disease Outcomes in a Rat Model of Epilepsy

Medical Journal of Babylon
Background: Oxidative stress and inflammation play an important role in the development of seizures. Gastrodia elata (GE) is a Chinese plant used for treating epileptic convulsions.
Noor-Alhuda Mohammed Alebadi, Reyadh H. Al-Mosawi, Mufeed Jalil Ewadh   +2 more
doaj   +1 more source

Zonisamide in the management of epilepsy in the elderly

Clinical Interventions in Aging, 2015
Andrea Romigi,1,2 Eti A Femia,3 Cinzia Fattore,4 Giuseppe Vitrani,1 Giancarlo Di Gennaro,1 Valentina Franco4 1Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy; 2Neurophysiopathology Department, University of Rome Tor Vergata, Rome,
Romigi A, Femia EA, Fattore C, Vitrani G, Di Gennaro G, Franco V   +5 more
doaj  

Zonisamide-loaded triblock copolymer nanomicelles as a novel drug delivery system for the treatment of acute spinal cord injury

International Journal of Nanomedicine, 2017
JingLun Li,1 JiaoJiao Deng,2 JinXian Yuan,1 Jie Fu,1 XiaoLing Li,2 AiPing Tong,2 YueLong Wang,2 YangMei Chen,1 Gang Guo2 1Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 2State Key Laboratory of ...
Li JL, Deng JJ, Yuan JX, Fu J, Li XL, Tong AP, Wang YL, Chen YM, Guo G   +8 more
doaj  

Probable drug-induced lupus erythematosus by zonisamide

JAAD Case Reports, 2021
Mohannad G. Safadi, BS, Kasey Smith, BS, MS, Shahzeb Hassan, BA, Viki Patel, MD, Michael Viglione, MD, PhD, Scott L. Zahner, MD, MS   +5 more
doaj   +1 more source

Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER. [PDF]

CNS Neurosci Ther
You L, Zhang D, Cheng Z, Qi Y, Qian R.
europepmc   +1 more source

Comparative Safety of Six First-Line Antiepileptic Monotherapies in Pediatric Epilepsy Using the United States FDA Adverse Event Reporting System. [PDF]

Cureus
Ogura T, Shiraishi C.
europepmc   +1 more source

Exploring the Antiamoebic Potential of Zonisamide and Perampanel against <i>Naegleria fowleri</i>: Insights from <i>In Vitro</i> and Docking Studies. [PDF]

ACS Omega
Rajendran K, Tayo L, Gomez M, Apparasamy D, Thevanayagam H, Velasco JA, Adremesin R, Dioso M, Shaik MF, Ahmed U, Anwar A, Kumar NK, Jones CI.   +12 more
europepmc   +1 more source

Efficacy of monotherapy with zonisamide and proposed reference interval in dogs with epilepsy: a cohort of 207 dogs (2011-2021). [PDF]

J Vet Intern Med
Thungrat K, Jukier T, Boothe DM.
europepmc   +1 more source